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Carriers of the apolipoprotein A-IMilano (A-IM) variant pres-
ent with severe reductions of plasma HDL levels, not associated
with premature coronary heart disease (CHD). Sera from 14
A-IM carriers and matched controls were compared for their
ability to promote ABCA1-driven cholesterol efflux from J774
macrophages and human fibroblasts. When both cell types are
stimulated to express ABCA1, the efflux of cholesterol through
this pathway is greater with A-IM than control sera (3.4 1.0%
versus 2.3 1.0% in macrophages; 5.2 2.4% versus 1.9 0.1%
in fibroblasts). A-IM and control sera are instead equally effec-
tive in removing cholesterol from unstimulated cells and from
fibroblasts not expressing ABCA1. The A-IM sera contain nor-
mal amounts of apoA-I-containing pre-HDL and varying con-
centrations of a unique small HDL particle containing a single
molecule of the A-IM dimer; chymase treatment of serum
degrades both particles and abolishes ABCA1-mediated choles-
terol efflux. The serum content of chymase-sensitive HDL cor-
relates strongly and significantly withABCA1-mediated choles-
terol efflux (r  0.542, p  0.004). The enhanced capacity of
A-IM serum for ABCA1 cholesterol efflux is thus explained by
the combined occurrence in serum of normal amounts of apoA-
I-containing pre-HDL, together with a unique protease-sensi-
tive, small HDL particle containing the A-IM dimer, both effec-
tive in removing cell cholesterol via ABCA1.
The efflux of cell cholesterol from the plasmamembrane into
suitable extracellular acceptors is the first, possibly rate-limit-
ing step in reverse cholesterol transport (1). Interest in studying
cell cholesterol efflux has increased with the discovery of a
number ofmembrane proteins that have nowbeen conclusively
shown to mediate the movement of cholesterol between cells
and extracellular acceptors, like the scavenger receptor BI (SR-
BI),2 and the ABCA1 and ABCG1 transporters (2). Cell choles-
terol efflux occurs through several mechanisms (3). Passive dif-
fusion into extracellular acceptors occurs from all cell types but
is relatively inefficient; when SR-BI is present in the cell plasma
membrane, the efflux is facilitated. Phospholipid-containing
HDL particles are the best acceptors of cholesterol through
both the diffusion-mediated and SR-BI-facilitated efflux. In
both cases, the flux of cholesterol is bidirectional, the direction
of net flux depending on the cholesterol gradient between the
cell membrane and the acceptor (3).
ABCA1 and ABCG1 are members of a large family of trans-
porters that have common structural motifs and use ATP as an
energy source to transport a variety of substrates, including
lipids, ions, and cytotoxins across the cell membrane (4).
ABCG1 is a half-transporter that might act as a homodimer,
mediating the active export of cholesterol and phospholipids to
the major forms of plasma HDL, such as HDL2 and HDL3 (5).
ABCA1, a full transporter comprising two similar halves linked
covalently, has been originally discovered as the genetic cause
of Tangier disease (TD), which is characterized by severe HDL
deficiency, accumulation of cholesterol in tissue macrophages,
and accelerated atherosclerosis. This finding highlights the
dual role of ABCA1 in HDL formation as well as in cholesterol
efflux from macrophages. ABCA1 is distributed both in the
plasma membrane and late endosomal compartments, cycling
between the two loci (6). ABCA1 expression is regulated by a
variety of mechanisms (7). In contrast to passive diffusion and
SR-BI-facilitated cholesterol flux, the movement of cholesterol
by ABCA1 is unidirectional and, accordingly, activation of this
system always results in net efflux of cell cholesterol (3). Also
different from SR-BI-facilitated cholesterol efflux, the pre-
ferred cholesterol acceptors via ABCA1 are lipid-free/poor
apolipoproteins. All of the exchangeable apolipoproteins, such
as apoA-I, apoA-II, apoA-IV, apoC, and apoE (8, 9), as well as
synthetic apoA-I-mimetic peptides (10) can act as cholesterol
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acceptors through ABCA1. In some instances, ABCA1 medi-
ates cholesterol efflux to plasma-derived HDL3 preparations,
this effect being attributable to the presence of pre-migrating
particles within the plasma HDL3 fraction (11).
The apolipoprotein A-IMilano (A-IM) mutation was originally
described in a family originating from Limone sul Garda, in
Northern Italy (12). This apoA-I variant shows a single amino
acid substitution, arginine 173 to cysteine, which leads to the
formation of homodimers (A-IM/A-IM) and heterodimers with
apoA-II (13). Forty-four carriers have been identified up to
now, all heterozygous for the mutation and sharing a lipopro-
tein phenotype characterized by very low plasma levels of HDL
cholesterol associated with moderate hypertriglyceridemia
(14), a condition that has been repeatedly linked to a high risk of
premature coronary heart disease (CHD). Surprisingly, the
A-IM carrier status was originally associated with a reduced
cardiovascular risk (15), a finding now supported by a recent
clinical study showing theA-IM carriers do not presentwith any
clear evidence of vascular disease at the preclinical level (16).
The apparent A-IM paradox of severe HDL deficiency with vas-
cular health may be explained by an enhanced capacity of the
carrier HDL to remove cholesterol from the arterial wall and
drive it to the liver for excretion. Such hypothesis was initially
investigated by comparing the capacity of serum from A-IM
carriers and from control subjects to extract cholesterol from
Fu5AH cells, which express high levels of SR-BI in the plasma
membrane, and thus efflux cholesterol mainly via SR-BI-facili-
tated diffusion. SR-BI-mediated cholesterol efflux to A-IM sera
was found to be only slightly reduced when compared with
control sera, despite the remarkable decrease in the content of
mature HDL, the preferential acceptors of SR-BI cholesterol
(17), suggesting a higher efficiency of A-IMHDL for cholesterol
uptake via this pathway. These previous investigations are com-
plemented in the present study, where we evaluated the ability
of sera from A-IM carriers and matched controls to promote
ABCA1-mediated cholesterol efflux from macrophages and
fibroblasts.
EXPERIMENTAL PROCEDURES
Subjects—Fourteen adult A-IM carriers (7 females, 7 males),
belonging to the previously described A-IM kindred (15) volun-
teered for this study. Fourteen age- and sex-matched noncarri-
ers were selected among close relatives in the same families. All
participating subjects were healthy, were taking no medica-
tions, and consumed a typical Mediterranean diet. All subjects
were fully informed of the modalities and end points of the
study. Fasting blood was collected into empty plastic tubes and
serum prepared by low speed centrifugation at 4 °C. Aliquots
were immediately frozen and stored at80 °C until assayed.
Reconstituted HDL—ApoA-I and A-IM/A-IM were purified
from human plasma, and discoidal reconstituted HDL (rHDL)
containing palmitoyloleoylphosphatidylcholine (POPC) and
either A-IM/A-IM or apoA-I, with a diameter of 7.8 nm, were
prepared by the cholate dialysis technique, as described (18). In
the final preparation, all the protein was incorporated into sta-
ble rHDL, with no lipid-free apolipoprotein remaining. The
apoA-I rHDL contained two apoA-I molecules, with a POPC:
apolipoprotein molar ratio of 44:1. The A-IM/A-IM rHDL con-
tained only oneA-IM/A-IMmolecule, with a POPC:apolipopro-
tein molar ratio of 73:1.
Analyses—Serum total and HDL cholesterol, triglyceride,
and phospholipid levels were determined with standard enzy-
matic techniques by using a Roche Diagnostics Integra 400
autoanalyzer. LDL cholesterol was calculated with the Friede-
wald formula. SerumapolipoproteinA-I, A-II, andB levelswere
determined by immunoturbidimetry, using the Integra 400
analyzer with commercially available polyclonal antibodies.
The sheep anti-human apoA-I antibody recognizes all forms of
A-IM (monomer, homodimer, and heterodimer); therefore the
apoA-I concentration determined in sera of A-IM carriers, who
are heterozygotes for the mutation, is the sum of mutant and
wild-type apoA-I.
Agarose Gel Electrophoresis—Agarose gel electrophoresis of
lipid-free apolipoproteins and rHDL was performed using the
Beckman Paragon system; proteins were stained with Coomas-
sie Blue G-250 (19).
Two-dimensional Electrophoresis and Immunoblotting—Se-
rum HDL subclasses were separated by two-dimensional elec-
trophoresis, in which agarose gel electrophoresis was followed
by nondenaturing polyacrylamide gradient gel electrophoresis
and subsequent immunoblotting (11). In the first dimension,
serum (5 l) was run on a 0.5% agarose gel; agarose gel strips
containing the separated lipoproteins were then transferred to
a 3–20% polyacrylamide gradient gel. Separation in the second
dimension was performed at 30 mA for 4 h. Fractionated HDL
were then electroblotted onto a nitrocellulose membrane and
detected with a sheep antihuman apoA-I antibody, which rec-
ognizes all forms of A-IM (monomer, homodimer, and het-
erodimer). Lipoproteins containing A-IM/A-IM were detected
with a mouse monoclonal antibody raised against A-IM/A-IM,
which does not recognize either other A-IM forms (monomer,
heterodimer) or wild-type apoA-I. The relative content of dis-
tinct HDL subclasses was calculated by using the Bio-Rad
Multi-Analyst/PC Software, and expressed as percentage of
total immunoreactivity.
Isolation of Mast Cell Granule Remnants—Serosalmast cells
were isolated from the peritoneal and pleural cavities of rats.
Degranulation was induced with compound 48/80 (Sigma) and
the exocytosed chymase-containing granules, i.e. granule rem-
nants, were isolated from the released material by centrifuga-
tion, as described (20). The heparin-bound chymase present in
granule remnants is partly resistant to inhibition by the physi-
ological antiproteases found in human serum, and, therefore,
addition of the remnants to serum results in progressive prote-
olysis of the various chymase-sensitive proteins present in
serum (21).
Proteolysis of Serum by Granule Remnant Chymase—500 l
of serum from 4A-IM carriers and 4 control subjects were incu-
bated in the absence or presence of granule remnants (30g/ml
of granule remnant total protein, equal to 40 BTEE units/ml)
for 2 h at 37 °C. After incubation, tubes were cooled down rap-
idly by placing them on ice. Tubes were centrifuged at 4 °C,
15,000 rpm for 5 min to remove the granule remnant-bound
chymase, and the chymase-free supernatants were collected
and used forHDL subclass separation by two-dimensional elec-
trophoresis and cell cholesterol efflux experiments. The HDL
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digestion products were analyzed by SDS-PAGE on 10–16%
acrylamide gradient slab gels, using the Tris-Tricine buffer sys-
tem, and then electrophoretically transferred to nitrocellulose
membranes (22). ApoA-I peptides were detected by the use of
the sheep antihuman apoA-I antibody, and A-IM/A-IM frag-
ments were detected by the use of the mouse anti A-IM/A-IM
monoclonal antibody.
Cell Culture—J774 mouse macrophages were cultured in
RPMI with 10% FCS. Human control and TD fibroblasts were
grown in Dulbecco’s modified Eagle’s medium with 10% FCS.
All cells seeded in 12-well plates and incubated at 37 °C, in 5%
CO2, and utilized when cultures have reached 80–90% of
confluence.
CPT-cAMP Stimulation—J774 monolayers were washed
with phosphate-buffered saline and incubated for 24 h in RPMI
containing [1,2-3H]cholesterol (4 Ci/ml), as described (23).
The labeling medium contained 1% FCS and 2 g/ml of an
ACAT inhibitor to ensure that all labeled cholesterol was pres-
ent as unesterified cholesterol. After the labeling period, cells
were washed and incubated in RPMI with 0.2% BSA, with or
without 0.3 mM CPT-cAMP for 18 h. After this incubation,
some wells were washed with PBS, dried, and extracted with
2-propyl alcohol. These cells provide baseline (time 0) values
for total [1,2-3H]cholesterol content. Human control and TD
fibroblasts were treated like J774 cells.
Measurement of Cell Cholesterol Efflux—CPT-cAMP-stimu-
lated and unstimulated monolayers containing [1,2-3H]choles-
terol were washed with phosphate-buffered saline and incu-
bated for efflux time (4 h) in the presence of 5% serum, or with
rHDL at the protein concentrations of 12.5 and 25.0g/ml. Cell
media were centrifuged to remove floating cells, and radioac-
tivity in the supernatant was determined by liquid scintillation
counting. Cholesterol efflux was calculated as: ((cpm in
medium at 4 h/cpm at time 0)  100). In some experiments,
efflux was evaluated after incubation of cells for 2 h with 10 M
probucol (24).
Statistical Analyses—Results are expressed as mean  S.D.
Differences among groups were evaluated by analysis of vari-
ance (one-way analysis of variance). Simple regression analyses
were performed to assess the association between parameters,
and the significance of the correlations was determined by
the F parameter and by the correlation coefficient. Group
differences or correlations with p  0.05 were considered
statistically significant.
RESULTS
Characteristics of the Population—The fasting serum lipid
and lipoprotein concentrations in the examined A-IM carriers
and controls are given in Table 1. Similar to previous studies
(14), the A-IM carriers had remarkably lower serum HDL-C,
apoA-I, and apoA-II levels and higher serum triglycerides than
did controls.
Cholesterol Efflux to Serum—Previous studies using Fu5AH
cells, which express high levels of SR-BI, have shown that the
A-IM serum contains lipoprotein particles with high efficiency
for cholesterol uptake via SR-BI-facilitated passive diffusion
(17). In the present study, the capacity of A-IM and control
serum to extract cell cholesterol via ABCA1 was initially tested
in J774 murine macrophages. Under basal conditions, the J774
macrophages express SR-BI, but not ABCA1, and releasemem-
brane cholesterol to extracellular acceptors mostly by passive
diffusion (25, 26). In such condition, cholesterol efflux to A-IM
sera was similar to efflux induced by control sera (10.8 1.9%
versus 11.9  1.2%). Stimulation of J774 macrophages with
CPT-cAMP induces ABCA1 expression and ABCA1-medi-
ated cholesterol efflux to lipid-free/-poor apolipoproteins
and pre-HDL (11). Indeed, when stimulated with CPT-
cAMP, the J774 cells released more cholesterol to serum
than did unstimulated J774 cells (14.2  1.6% to A-IM sera
and 14.2 1.0% to control sera). The ABCA1-mediated cho-
lesterol efflux was calculated as the percentage efflux from
stimulated J774 cells minus the percentage efflux from
unstimulated cells. There was a biological variability within
the two groups; however, on average, ABCA1-dependent
cholesterol efflux to serum from A-IM carriers was signifi-
cantly greater (3.4  1.0%) than efflux to serum from con-
trols (2.3  1.0%, p  0.013) (Fig. 1).
To demonstrate further that A-IM serum is more effective
than control serum in promoting cell cholesterol efflux through
FIGURE 1.ABCA1-mediated cholesterol efflux from J774macrophages to
sera from A-IM carriers and controls. Macrophages were labeled with 4
Ci/ml [3H]cholesterol for 24 h in RPMI medium with 1% FCS and 2 g/ml of
an ACAT inhibitor. Cells were then incubated for 18 h with 0.2% BSA in the
absence or presence of 0.3mMCPT-cAMP,washed and incubated for 4 hwith
5% serum. Each sample was run in triplicate. ABCA1-mediated cholesterol
efflux was calculated as the percentage efflux from CPT-cAMP-stimulated
cells minus the percentage efflux from unstimulated cells. The box plot dis-
playsmedian values with the 25th and 75th percentiles; capped bars indicate
the 10th and 90th percentiles. Each group consists of 14 subjects.
TABLE 1
Serum lipid/lipoprotein levels in A-IM carriers and controls
A-IM carriers Controls p
Gender (M/F) 7/7 7/7
Age (y) 41.1 17.4a 39.0 14.3 NSb
BMI (kg/m2) 24.4 4.3 24.0 3.6 NS
Total cholesterol (mg/dl) 184.3 46.1 210.6 50.8 NS
LDL cholesterol (mg/dl) 130.0 13.3 138.6 43.7 NS
HDL cholesterol (mg/dl) 21.9 11.0 49.7 20.6 0.001
Triglycerides (mg/dl) 155.6 65.1 111.9 37.3 0.023
Phospholipids (mg/dl) 222.8 83.4 247.8 60.5 NS
ApoA-I (mg/dl) 83.1 31.6 132.6 21.5 0.001
ApoA-II (mg/dl) 17.8 5.5 40.3 7.1 0.001
ApoB (mg/dl) 99.2 30.2 86.6 24.8 NS
Pre-HDL (%) 15.6 5.1 15.5 3.3 NS
aData are reported as mean S.D.
bNS, not significant.
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ABCA1, two sets of experiments were performed. First, before
assessment of cell cholesterol efflux, unstimulated and cAMP-
stimulated J774 cells were treated with probucol, a selective
inhibitor of ABCA1-mediated lipid efflux (24). Probucol com-
pletely abolished the cAMP-induced increase in cholesterol
efflux to both A-IM serum (11.6 0.8% from cAMP-stimulated
cells versus 11.5  2.2% from unstimulated cells) and control
serum (13.5 0.3% from cAMP-stimulated cells versus 13.0
1.7% from unstimulated cells). Second, cell cholesterol efflux to
A-IM and control sera was assessed by using skin fibroblasts
from a healthy individual and from a patient with TD. A-IM and
control sera displayed the same capacity to extract cholesterol
from unstimulated control fibroblasts (Fig. 2); cAMP stimula-
tion of these cells enhanced cholesterol efflux to serum, the
enhancement being significantly greater to sera fromA-IM car-
riers (5.2  2.4%) than to sera from controls (1.8  0.1%, p 
0.001) (Fig. 2). In sharp contrast, when sera were added to stim-
ulated TD fibroblasts, which do not express ABCA1, no cAMP-
induced increase in cholesterol efflux was observed with either
type of serum (Fig. 2). These findings provide definite evidence
that serum from A-IM carriers is more effective than control
serum in removing cell cholesterol via ABCA1.
Serum HDL Subclasses and ABCA1-mediated Cell Choles-
terol Efflux—To identify the component of A-IM serum respon-
sible for the improved cholesterol efflux capacity via the
ABCA1 transporter, sera from A-IM and control subjects were
analyzed for their apoA-I-containing subpopulations by two-
dimensional electrophoresis and immunoblotting. We have
previously shown that control small pre-migrating HDL,
uniquely sensitive to proteolytic degradation by chymase, are a
very efficient acceptor for ABCA1-mediated cholesterol efflux
(11). A similar small pre-migrating HDL is detectable in A-IM
sera; it contains wild-type apoA-I, consistent with the fact that
the A-IM carriers are all heterozygous for the mutation, but not
the A-IM/A-IM, as no signal was detected in the pre- region by
using an antibody specific for the homodimeric form of A-IM
(Fig. 3). This particle is therefore identical to apoA-I-containing
small pre-HDL found in control serum. We then determined
the relative proportion of pre-HDL in the sera fromA-IM car-
riers and controls. No difference was observed between the two
groups of subjects (Table 1), suggesting that components of
A-IM serum other than the small apoA-I-containing pre-HDL
were responsible for the enhanced ABCA1-mediated choles-
terol efflux to A-IM sera. Interestingly, immunodetection of
A-IM HDL subclasses with the anti A-IM/A-IM antibody iden-
tified two sets of particles: a series of-migratingHDLparticles
ranging in diameter from 8.5 to 13 nm, i.e. in the range of con-
trol -HDL, and a small HDL particle, with an estimated diam-
eter of 7.8 nm,migrating in a position intermediate between the
pre and the  regions (Fig. 3). Such particle has an apparent
molecular mass of 92 kDa, and thus likely contains one A-IM/
A-IM molecule (56 kDa) as the sole protein component with
45–50 phospholipid molecules. No signal for apoA-II was
detectable in this region, indicating that this particle contains
neither apoA-II nor the heterodimer A-IM/A-II (not shown).
According to densitometric analysis, these particles accounted
for 22.2 6.5%of total A-IM/A-IM immunoreactivity. To inves-
tigate whether this unique A-IM/A-
IM-containing HDL particle acts
as cell cholesterol acceptor via
ABCA1, sera from A-IM carriers
and controls were treated with chy-
mase, previously shown to specifi-
cally and completely abolish the
ABCA1-mediated component of
cell cholesterol efflux to control
HDL through degradation of pre-
HDL, without affecting cell choles-
terol efflux through other pathways,
e.g. SR-BI or passive diffusion (11).
As expected, chymase treatment
of control serum resulted in the
complete degradation of pre-
HDL particles (Fig. 3). Similarly, in
chymase-treatedA-IM sera, apoA-I-
FIGURE 2. Cholesterol efflux from human control and TD fibroblasts to
sera from A-IM carriers and controls. Cell monolayers were labeled with 4
Ci/ml [3H]cholesterol for 24 h in Dulbecco’s modified Eagle’s medium with
1% FCS and 2 g/ml of an ACAT inhibitor. Cells were then incubated for 18 h
with 0.2% BSA in the absence (open bars) or presence (filled bars) of 0.3 mM
CPT-cAMP, washed and incubated for 4 h with 5% serum. Cholesterol efflux
was calculated as: ((cpm inmediumat 4 h/cpmat time 0) 100). Each sample
was run in triplicate. Data are mean S.D.; n 4.
FIGURE3.Effectof chymase treatmentonHDLsubclasses in serumfromA-IMcarriersandcontrols.Serum
was incubated with chymase-containing granule remnants for 2 h at 37 °C. At the end of the incubation, HDL
subclasses were separated by two-dimensional electrophoresis and transferred onto a nitrocellulose mem-
brane, on which lipoproteins were detected with a sheep anti-human apoA-I antibody, which recognizes also
all forms of A-IM (monomer, homodimer, and heterodimer), and with a mouse monoclonal antibody against
A-IM/A-IM, which does not recognize either other A-IM forms (monomer, heterodimer) or wild-type apoA-I. The
small HDL containing A-IM/A-IM andmigrating in a position intermediate between the pre and the  regions
is indicated with a circle.
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containing pre-HDL were fully degraded (Fig. 3). In addition,
after chymase treatment of A-IM serum, the unique A-IM/A-
IM-containing HDL particle was no more detectable by either
anti apoA-I or anti A-IM/A-IM antibody (Fig. 3). Analysis of the
various chymase-treated sera by SDS-PAGE and immunode-
tection of apoA-I and A-IM/A-IM, showed fragmentation of
these proteins by chymase (Fig. 4). Chymase-treated sera were
added to unstimulated and cAMP-stimulated J774 macro-
phages to measure ABCA1-independent and -dependent cell
cholesterol efflux. As expected, chymase-treated sera were able
to remove cell cholesterol through pathways other than
ABCA1, e.g. SR-BI and passive diffusion (11), with no signifi-
cant difference between A-IM and control sera (Fig. 5); this is
consistentwith findings fromprevious studies (17), inwhichwe
looked at the ability of A-IM sera to remove cell cholesterol
from Fu5AH cells, which express SR-BI but not ABCA1 (27).
No cAMP-induced increase in cholesterol efflux was observed
with either control or A-IM sera (Fig. 5). This clearly indicates
that simultaneous depletion of both the pre-HDL and the
unique A-IM/A-IM-containing HDL abolishes ABCA1-
dependent efflux induced by A-IM serum, a finding compatible
with the idea that both these particles can remove macrophage
cholesterol via ABCA1. To prove that this is indeed the case, we
investigated the association between the serum content of chy-
mase-sensitive HDL subclasses, i.e. pre-HDL plus the unique
A-IM/A-IM-containing HDL in A-IM serum and pre-HDL in
control serum, and the serum capacity to promotemacrophage
cholesterol efflux via ABCA1. The serum content of chymase-
sensitive HDL ranged from 23.7 to 47.6% (33.3 6.8%) in A-IM
carriers, and from11.7 to 22.0% in controls (15.5 3.3%). In the
whole series of sera, the content of chymase-sensitive HDLwas
strongly and significantly correlated with ABCA1-mediated
cholesterol efflux to serum (r 0.542, p 0.004) (Fig. 6). Alto-
gether, these findings allow us to conclude that the unique
A-IM/A-IM-containing HDL particle is an efficient acceptor of
cell cholesterol exported via the ABCA1 transporter like the
control pre-HDL, and that the simultaneous presence of the
two particles explains the enhanced capacity of theA-IM sera to
induce ABCA1-mediated cell cholesterol efflux.
Cholesterol Efflux from J774 Macrophages to rHDL Contain-
ing A-IM/A-IM or apoA-I—To investigate the impact of the dis-
tinct protein composition of the unique A-IM/A-IM-containing
HDL particle and the apoA-I-containing pre-HDL on their
capacity to remove macrophage cholesterol via ABCA1, rHDL
containing exclusivelyA-IM/A-IM or apoA-Iwere prepared and
tested for their ability to induce cholesterol efflux from J774
macrophages. The two rHDL particles have the same size (7.8
nm) and phospholipid content, and contain 1 A-IM/A-IM or 2
apoA-I molecules per particle (18). While apoA-I rHDL
migrate in the pre position on agarose gels, the A-IM/A-IM
rHDL migrate faster, so reaching a position intermediate
between the pre and the  regions, like the unique A-IM/A-
FIGURE 4. Effect of chymase treatment on HDL apolipoproteins in serum
from A-IM carriers and controls. Serum was incubated with chymase-con-
taining granule remnants for 2 h at 37 °C. At the end of the incubation, HDL
apolipoproteins were separated by SDS-PAGE and transferred onto a nitro-
cellulose membrane on which apolipoproteins were detected with a sheep
anti-human apoA-I antibody, which recognizes also all forms of A-IM (mono-
mer, homodimer, and heterodimer), andwith amousemonoclonal antibody
against A-IM/A-IM, which does not recognize either other A-IM forms (mono-
mer, heterodimer) or wild-type apoA-I.
FIGURE 5. Effect of chymase treatment of sera fromA-IM carriers and con-
trols on serum-induced cholesterol efflux from J774 macrophages. Sera
were pretreated with chymase-containing granule remnants for 2 h at 37 °C.
Macrophages were labeled with 4 Ci/ml [3H]cholesterol for 24 h in RPMI
mediumwith 1% FCS, incubated for 18 hwith 0.2% BSA in the absence (open
bars) or presence (filled bars) of 0.3 mM CPT-cAMP, washed and incubated for
4 h with 5% of either untreated (left) or chymase-treated (right) serum. Cho-
lesterol efflux was calculated as: ((cpm in medium at 4 h/cpm at time 0) 
100). Each sample was run in triplicate. Data are mean S.D.; n 4.
FIGURE 6. Correlation between ABCA1-mediated cholesterol efflux to
serum and chymase-sensitive HDL subclasses. The serum capacity to pro-
mote ABCA1-mediated cholesterol efflux, calculated as the percentage efflux
from CPT-cAMP-stimulated J774 macrophages minus the percentage efflux
from unstimulated J774 cells, was plotted versus the serum content of HDL
particles sensitive to chymase degradation, expressed as percentage of total
apoA-I.
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IM-containing HDL found in the A-IM serum (Fig. 7). This
migration likely reflects a different surface charge of themutant
versus wild-type protein; indeed, the purified lipid-free A-IM/
A-IM also migrates in the same position as A-IM/A-IM rHDL
(Fig. 7). Consistent with previous findings in Fu5AH cells (28),
unstimulated J774 macrophages released more cholesterol to
A-IM/A-IM rHDL than apoA-I rHDL (Fig. 8); as expected, very
little cholesterol efflux occurred to the lipid-free apolipopro-
teins (apoA-I: 0.59 0.16%; A-IM/A-IM: 0.40 0.02%; both at
12.5 g/ml). Stimulation of cells with CPT-cAMP enhanced
cell cholesterol efflux to rHDL (Fig. 8).WhenABCA1-mediated
cholesterol efflux was calculated as the percentage efflux from
stimulated J774 cells minus the percentage efflux from
unstimulated cells, no difference was observed between A-IM/
A-IM and apoA-I rHDL (2.2  0.3% versus 2.4  0.1% at 12.5
g/ml and 3.2  0.3% versus 3.1  0.1% at 25.0 g/ml). Con-
sistentwith previous data (11), the lipid-free apolipoproteinswere
more effective than rHDL in removing cell cholesterol viaABCA1,
again with no significant difference between A-IM/A-IM and
apoA-I (4.8 0.4% versus 5.5 0.2%; both at 12.5g/ml).
DISCUSSION
The present study demonstrates that the serum from A-IM
carriers is more efficient than the serum from control subjects
in promoting cell cholesterol efflux through the ABCA1 path-
way. In cholesterol efflux studies with whole serum, the effi-
ciency of cholesterol efflux is likely determined by individual
variations in the serum content of a variety of potential accep-
tors (29). We have previously demonstrated that the ABCA1-
dependent cholesterol efflux to control HDL has small apoA-I-
containing pre-HDL as preferential acceptors (11). Here we
show that sera from various A-IM carriers contain normal
amounts of such small apoA-I-containing pre-HDL, together
with varying concentrations of a unique HDL particle, a small
A-IM/A-IM-containingHDLwith electrophoreticmigration on
agarose gel intermediate between the pre and the  regions.
Limited proteolysis of A-IM serum with chymase degrades the
small A-IM/A-IM-containing HDL particle, as well as apoA-I-
containing pre-HDL, and completely abolishes ABCA1-me-
diated cholesterol efflux. Moreover, rHDL made with A-IM/
A-IM, resembling the small A-IM/A-IM-containing HDL found
in A-IM serum, are as effective as rHDL containing apoA-I,
which resemble serum pre-HDL, as cholesterol acceptors via
ABCA1. Finally, in the whole series of examined samples, the
serum content of chymase-sensitive HDL is strongly correlated
with ABCA1-dependent cholesterol efflux to whole serum.
Altogether these findings indicate the enhanced efficiency of
A-IM serum in promoting ABCA1-mediated cell cholesterol
efflux is caused by the simultaneous presence of the unique
small A-IM/A-IM-containingHDL particles and the pre-HDL,
all equally effective in inducing efflux of cholesterol via ABCA1.
There is clear evidence that lipid-free apolipoproteins are the
preferred lipid acceptors for ABCA1-mediated efflux; all of the
exchangeable apolipoproteins, such as apoA-I, apoA-II, and
apoA-IV, can act as cholesterol and phospholipid acceptors for
ABCA1 (8, 9). Apolipoprotein lipidation through ABCA1
results in the formation of discoidal, nascent HDL which than
mature into spherical HDL through the action of the lecithin:
cholesterol acyltransferase (LCAT) enzyme (30); such mature
HDL remove further cell cholesterol through either SR-BI or
ABCG1 (31). We have earlier shown that lipid-free A-IM/A-IM
is as effective as apoA-I in removing cholesterol from choles-
terol-loaded macrophages (28), a process now known to be
mostly dependent on ABCA1 (2). Moreover, CHO cells trans-
fected with the A-IM gene secrete A-IM/A-IM, which then gen-
erates small discoidal HDL particles (32), likely through inter-
action with ABCA1 (30). These nascent HDL contain one
molecule of A-IM/A-IM (32), thus resembling the A-IM/A-IM-
HDL found here in A-IM serum, being however somewhat
smaller in size. Therefore, lipid-free A-IM/A-IM is fully active in
generating nascent HDL particles via ABCA1. Nascent A-IM/
A-IM-HDL slowly remodel into larger, spherical HDL because
of a high intrinsic stability conferred by the disulfide-linked
dimer (33), and a reduced ability of the dimer to interact with,
and activate LCAT (34). Indeed, kinetic studies in A-IM carriers
FIGURE 7.Agarosegel electrophoresis of rHDL containing apoA-I orA-IM/
A-IM, andof the lipid-freeapolipoproteins. rHDLcontainingapoA-I orA-IM/
A-IM and POPC (left), and lipid-free apoA-I and A-IM/A-IM (right) were run on
agarose gels and stained with Coomassie Blue G-250.
FIGURE 8. Cholesterol efflux from J774macrophages to rHDL containing
A-IM/A-IM or apoA-I. Macrophages were labeled with 4 Ci/ml [
3H]choles-
terol for 24 h in RPMImediumwith 1% FCS, incubated for 18 hwith 0.2% BSA
in the absence (open bars) or presence (filled bars) of 0.3 mM CPT-cAMP,
washed and incubated for 4 hwith rHDL containing A-IM/A-IM (left), or apoA-I
(right) at the protein concentration of 12.5 and 25 g/ml. Data are mean 
S.D. of a representative experiment performed in triplicate.
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showed a normal A-IM/A-IM production rate together with a
remarkable delay in A-IM/A-IM catabolism (35, 36).
In addition to lipid-free apolipoproteins, ultracentrifugally
isolated plasma HDL can promote cholesterol efflux via
ABCA1, this effect being attributed to small pre-HDL com-
monly found in the serumHDL fraction (11). These small pre-
HDLaccount for10%of totalHDL innormal serum, and their
serum concentration increases in pathological conditions, like
primary biliary cirrhosis (37) or LCAT deficiency (38). Notably,
the serum content of small pre-HDL has been reported to
correlate with ABCA1-mediated efflux to whole serum in a
number of studies (37, 39). Moreover, interventions leading to
enrichment of controlHDL fraction orwhole plasmawith small
pre-HDL result in parallel increases inABCA1-dependent cell
lipid release (11, 40). These small pre-HDL are likely discoidal
in shape, and reportedly contain only apoA-I with a few phos-
pholipidmolecules per particle (41). The role of HDL phospho-
lipids in ABCA1-mediated efflux has not been carefully exam-
ined, but there is evidence that the addition of a certain amount
of phospholipids to apoA-I does not impair its capacity to inter-
act with ABCA1 and promote cell cholesterol efflux (42). This
concept is further supported by the present experiment with
small apoA-I-containing rHDL, which are able to promote cell
cholesterol efflux through ABCA1, although less effectively
than the lipid-free apolipoprotein. Small A-IM/A-IM-contain-
ing rHDL are as good as apoA-I-containing rHDL in removing
cell cholesterol through ABCA1. Notably, the C terminus of
both apoA-I and A-IM/A-IM is distinctively exposed in discoi-
dal small HDL (22), possibly facilitating the interactionwith the
cell membrane prior to ABCA1 binding to promote cell choles-
terol efflux (43, 44).
The results of the present study integrate those of earlier
investigations in providing a plausible explanation for the
apparent A-IM paradox, where subjects with severe reductions
in the plasma concentration of antiatherogenic HDL do not
present with preclinical atherosclerosis and premature CHD
(16). We have previously shown that the SR-BI-mediated cho-
lesterol efflux to sera fromA-IM carriers is only slightly reduced
comparedwith efflux to control sera (17). SR-BI-mediated cho-
lesterol efflux to serum is strongly correlated to the serum
apoA-I and HDL cholesterol levels (17), which likely reflect the
content of mature HDL particles, the best acceptors for cell
cholesterol through SR-BI (2). The slight reduction of SR-BI
mediated cholesterol efflux to A-IM serum despite the severe
reduction in serum apoA-I and HDL-cholesterol levels was
thus interpreted as being due to an enhanced efficiency of
mature A-IM-containing HDL particles in accepting cell cho-
lesterol through SR-BI (17). Indeed, rHDL containing the
dimeric form of A-IM were more efficient than rHDL contain-
ing apoA-I of comparable size in promoting cholesterol efflux
from Fu5AH cells (28), which express SR-BI but not ABCA1
(27). Consistentwith these previous findings, we showhere that
theA-IM/A-IM-containing rHDL aremore effective than apoA-
I-containing rHDL in removing cholesterol from unstimulated
J774 macrophages (Fig. 8) which also likely express SR-BI (25)
but not ABCA1 (26).
Here we nowdemonstrate that serum fromA-IM carriers has
a greater cholesterol efflux capacity through ABCA1 than
serum from control subjects. Although the ABCA1-mediated
efflux to serum is lower than efflux from unstimulated cells,
likely due to the presence in serum of a variety of acceptors for
cell cholesterol via SR-BI and ABCG1 (45, 46), it is a unidirec-
tional process, resulting in net cholesterol removal from donor
cells. The enhanced capacity of A-IM serum for ABCA1 choles-
terol is due to the presence of a unique small A-IM/A-IM-con-
taining HDL particle with the same efficiency of common
apoA-I-containing pre-HDL particles in removing cell cho-
lesterol. Notably, the direct infusion of small A-IM/A-IM-con-
taining synthetic HDL in animals has shown these particles are
able to penetrate into the atherosclerotic plaque, remove cho-
lesterol from macrophages and cause a rapid regression of the
atherosclerotic lesion (47). Even more strikingly, a short term
treatment with the same synthetic HDL caused a regression of
atherosclerotic lesions in coronary patients (48). If, as generally
believed, ABCA1 is themost significant factor in removing cho-
lesterol from macrophages, thus preventing atherosclerosis
development (49), the present findings would provide mecha-
nistic support to further development of A-IM/A-IM-contain-
ing synthetic HDL for the treatment of CHD. Whether the
enhanced capacity of A-IM serum for ABCA1-mediated efflux
contributes to the lack of preclinical atherosclerosis andprema-
ture CHD in the carriers is presently difficult to predict, con-
sidering the still unknown relative contributions of the various
HDL functions, e.g. cell cholesterol removal, anti-inflamma-
tion, and anti-oxidant, in HDL-mediated atheroprotection
(50), and the peculiar anti-inflammatory and anti-oxidant
properties of the A-IMmutant versuswild-type apoA-I (51, 52).
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